Back to News
Market Impact: 0.42
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Source: reuters.com
Healthcare & Biotech
Otsuka Pharmaceutical and Ionis Pharmaceuticals said their experimental therapy met the primary endpoint in a late-stage trial for a rare inherited form of ALS. The positive pivotal-study result could support regulatory filings and improve the commercial outlook for both companies' rare-disease pipelines.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
IONS0.78
More News
- JPMorgan cuts Ionis Pharmaceuticals stock price target on launch concerns
- Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
- Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas
- In Senegal, a mother’s ordeal exposes a health system under strain